Considerations for anti-PD1-based first-line treatment of Hodgkin lymphoma

被引：1

作者：

Broeckelmann, Paul J. ^{[1
,2
,3
,4
,5
,6
]}

机构：

[1] Univ Cologne, Dept Internal Med 1, Fac Med, Cologne, Germany

[2] Univ Cologne, Univ Hosp Cologne, Ctr Integrated Oncol Aachen Bonn Cologne Duesseldo, Cologne, Germany

[3] German Hodgkin Study Grp GHSG, Cologne, Germany

[4] Max Planck Inst Biol Ageing, Max Planck Res Grp Mech DNA Repair, Cologne, Germany

[5] Univ Hosp Cologne, Fac Med, Dept Internal Med 1, Kerpener Str 62, D-50937 Cologne, Germany

[6] Univ Hosp Cologne, Ctr Integrated Oncol Aachen Bonn Cologne Duesseldo, Kerpener Str 62, D-50937 Cologne, Germany

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2024年 / 205卷 / 01期

关键词：

anti-PD1; Hodgkin lymphoma; pembrolizumab;

D O I：

10.1111/bjh.19534

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Anti-PD1-based first-line treatment holds great promise in classical Hodgkin lymphoma. The management of immune-related adverse events in the context of time-limited combined checkpoint blockade and chemotherapy administered in curative intent is a challenge. Kuczmarski and Lynch provide a case-based approach to key toxicities observed in this setting.

引用

页码：22 / 24

页数：3

共 50 条

[1] Cost considerations in the first-line treatment of advanced Hodgkin lymphoma
Perissinotti, Anthony J.
LANCET HAEMATOLOGY, 2020, 7 (02): : E91 - E93
[2] First-Line Treatment of Hodgkin Lymphoma
Engert, Andreas
TURKISH JOURNAL OF HEMATOLOGY, 2019, 36 : 17 - 18
[3] First-line treatment of Hodgkin lymphoma
Federico, Massimo
LEUKEMIA RESEARCH, 2018, 73 : S10 - S10
[4] First-line treatment of Hodgkin's lymphoma
Klimm B.
Engert A.
Diehl V.
Current Hematologic Malignancy Reports, 2006, 1 (1) : 51 - 59
[5] Reverted exhaustion phenotype of circulating lymphocytes as immune correlate of anti-PD1 first-line treatment in Hodgkin lymphoma
Maria A. Garcia-Marquez
Martin Thelen
Sarah Reinke
Diandra Keller
Kerstin Wennhold
Jonas Lehmann
Johanna Veldman
Sven Borchmann
Andreas Rosenwald
Stephanie Sasse
Arjan Diepstra
Peter Borchmann
Andreas Engert
Wolfram Klapper
Michael von Bergwelt-Baildon
Paul J. Bröckelmann
Hans A. Schlößer
Leukemia, 2022, 36 : 760 - 771
[6] Reverted exhaustion phenotype of circulating lymphocytes as immune correlate of anti-PD1 first-line treatment in Hodgkin lymphoma
Garcia-Marquez, Maria A.
Thelen, Martin
Reinke, Sarah
Keller, Diandra
Wennhold, Kerstin
Lehmann, Jonas
Veldman, Johanna
Borchmann, Sven
Rosenwald, Andreas
Sasse, Stephanie
Diepstra, Arjan
Borchmann, Peter
Engert, Andreas
Klapper, Wolfram
Von Bergwelt-Baildon, Michael
Broeckelmann, Paul J.
Schloesser, Hans A.
LEUKEMIA, 2022, 36 (03) : 760 - 771
[7] The role of PET in first-line treatment of Hodgkin lymphoma
Trotman, Judith
Barrington, Sally F.
LANCET HAEMATOLOGY, 2021, 8 (01): : E67 - E79
[8] Bendamustine-based therapy as first-line treatment for non-Hodgkin lymphoma
Lidia Gil
Maciej Kazmierczak
Renata Kroll-Balcerzak
Mieczyslaw Komarnicki
Medical Oncology, 2014, 31
[9] Bendamustine-based therapy as first-line treatment for non-Hodgkin lymphoma
Gil, Lidia
Kazmierczak, Maciej
Kroll-Balcerzak, Renata
Komarnicki, Mieczyslaw
MEDICAL ONCOLOGY, 2014, 31 (05) : 1 - 7
[10] Incorporating Monoclonal Antibodies into the First-Line Treatment of Classical Hodgkin Lymphoma
Vassilakopoulos, Theodoros P.
Liaskas, Athanasios
Pereyra, Patricio
Panayiotidis, Panayiotis
Angelopoulou, Maria K.
Gallamini, Andrea
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (17)

← 1 2 3 4 5 →